Terms: = Ovarian cancer AND PSA AND Diagnosis
57 results:
1. Latin America and the Caribbean Code Against cancer 1st Edition: Medical interventions including hormone replacement therapy and cancer screening.
Baena A; Paolino M; Villarreal-Garza C; Torres G; Delgado L; Ruiz R; Canelo-Aybar C; Song Y; Feliu A; Maza M; Jeronimo J; Espina C; Almonte M
Cancer Epidemiol; 2023 Oct; 86 Suppl 1():102446. PubMed ID: 37852728
[TBL] [Abstract] [Full Text] [Related]
2. Prostate cancer Incidence and Mortality Following a Negative Biopsy in a Population Undergoing psa Screening.
Pierre-Victor D; Parnes HL; Andriole GL; Pinsky PF
Urology; 2021 Sep; 155():62-69. PubMed ID: 34186135
[TBL] [Abstract] [Full Text] [Related]
3. Body size throughout the life-course and incident benign prostatic hyperplasia-related outcomes and nocturia.
Khan S; Wolin KY; Pakpahan R; Grubb RL; Colditz GA; Ragard L; Mabie J; Breyer BN; Andriole GL; Sutcliffe S
BMC Urol; 2021 Mar; 21(1):47. PubMed ID: 33773592
[TBL] [Abstract] [Full Text] [Related]
4. Identification of six novel alternative transcripts of the human kallikrein-related peptidase 15 (KLK15), using 3'RACE and high-throughput sequencing.
Adamopoulos PG; Koukouzeli FΕ; Kontos CK; Scorilas A
Gene; 2020 Jul; 749():144708. PubMed ID: 32334022
[TBL] [Abstract] [Full Text] [Related]
5. Association of Baseline Prostate-Specific Antigen Level With Long-term diagnosis of Clinically Significant Prostate cancer Among Patients Aged 55 to 60 Years: A Secondary Analysis of a Cohort in the Prostate, Lung, Colorectal, and ovarian (PLCO) cancer Screening Trial.
Kovac E; Carlsson SV; Lilja H; Hugosson J; Kattan MW; Holmberg E; Stephenson AJ
JAMA Netw Open; 2020 Jan; 3(1):e1919284. PubMed ID: 31940039
[TBL] [Abstract] [Full Text] [Related]
6. Nanoparticle-aided glycovariant assays to bridge biomarker performance and ctDNA results.
Gidwani K; Kekki H; Terävä J; Soukka T; Sundfeldt K; Pettersson K
Mol Aspects Med; 2020 Apr; 72():100831. PubMed ID: 31787337
[TBL] [Abstract] [Full Text] [Related]
7. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.
Page EC; Bancroft EK; Brook MN; Assel M; Hassan Al Battat M; Thomas S; Taylor N; Chamberlain A; Pope J; Raghallaigh HN; Evans DG; Rothwell J; Maehle L; Grindedal EM; James P; Mascarenhas L; McKinley J; Side L; Thomas T; van Asperen C; Vasen H; Kiemeney LA; Ringelberg J; Jensen TD; Osther PJS; Helfand BT; Genova E; Oldenburg RA; Cybulski C; Wokolorczyk D; Ong KR; Huber C; Lam J; Taylor L; Salinas M; Feliubadaló L; Oosterwijk JC; van Zelst-Stams W; Cook J; Rosario DJ; Domchek S; Powers J; Buys S; O'Toole K; Ausems MGEM; Schmutzler RK; Rhiem K; Izatt L; Tripathi V; Teixeira MR; Cardoso M; Foulkes WD; Aprikian A; van Randeraad H; Davidson R; Longmuir M; Ruijs MWG; Helderman van den Enden ATJM; Adank M; Williams R; Andrews L; Murphy DG; Halliday D; Walker L; Liljegren A; Carlsson S; Azzabi A; Jobson I; Morton C; Shackleton K; Snape K; Hanson H; Harris M; Tischkowitz M; Taylor A; Kirk J; Susman R; Chen-Shtoyerman R; Spigelman A; Pachter N; Ahmed M; Ramon Y Cajal T; Zgajnar J; Brewer C; Gadea N; Brady AF; van Os T; Gallagher D; Johannsson O; Donaldson A; Barwell J; Nicolai N; Friedman E; Obeid E; Greenhalgh L; Murthy V; Copakova L; Saya S; McGrath J; Cooke P; Rønlund K; Richardson K; Henderson A; Teo SH; Arun B; Kast K; Dias A; Aaronson NK; Ardern-Jones A; Bangma CH; Castro E; Dearnaley D; Eccles DM; Tricker K; Eyfjord J; Falconer A; Foster C; Gronberg H; Hamdy FC; Stefansdottir V; Khoo V; Lindeman GJ; Lubinski J; Axcrona K; Mikropoulos C; Mitra A; Moynihan C; Rennert G; Suri M; Wilson P; Dudderidge T; ; Offman J; Kote-Jarai Z; Vickers A; Lilja H; Eeles RA
Eur Urol; 2019 Dec; 76(6):831-842. PubMed ID: 31537406
[TBL] [Abstract] [Full Text] [Related]
8. Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and ovarian randomized cancer screening trial.
Pinsky PF; Miller E; Prorok P; Grubb R; Crawford ED; Andriole G
BJU Int; 2019 May; 123(5):854-860. PubMed ID: 30288918
[TBL] [Abstract] [Full Text] [Related]
9. Male BRCA mutation carriers: clinical characteristics and cancer spectrum.
Ibrahim M; Yadav S; Ogunleye F; Zakalik D
BMC Cancer; 2018 Feb; 18(1):179. PubMed ID: 29433453
[TBL] [Abstract] [Full Text] [Related]
10. A prospective study of mitochondrial DNA copy number and the risk of prostate cancer.
Moore A; Lan Q; Hofmann JN; Liu CS; Cheng WL; Lin TT; Berndt SI
Cancer Causes Control; 2017 Jun; 28(6):529-538. PubMed ID: 28357528
[TBL] [Abstract] [Full Text] [Related]
11. Prostate Specific Antigen-Growth Curve Model to Predict High-Risk Prostate cancer.
Shoaibi A; Rao GA; Cai B; Rawl J; Haddock KS; Hébert JR
Prostate; 2017 Feb; 77(2):173-184. PubMed ID: 27699819
[TBL] [Abstract] [Full Text] [Related]
12. The use of multiphase nonlinear mixed models to define and quantify long-term changes in serum prostate-specific antigen: data from the Prostate, Lung, Colorectal, and ovarian cancer Screening Trial.
Shoaibi A; Rao GA; Cai B; Rawl J; Hébert JR
Ann Epidemiol; 2016 Jan; 26(1):36-42.e1-2. PubMed ID: 26611771
[TBL] [Abstract] [Full Text] [Related]
13. Biomarker development, from bench to bedside.
Stenman UH
Crit Rev Clin Lab Sci; 2016; 53(2):69-86. PubMed ID: 26287282
[TBL] [Abstract] [Full Text] [Related]
14. Prostate genetic score (PGS-33) is independently associated with risk of prostate cancer in the PLCO trial.
Liss MA; Xu J; Chen H; Kader AK
Prostate; 2015 Sep; 75(12):1322-8. PubMed ID: 25982801
[TBL] [Abstract] [Full Text] [Related]
15. Sexually transmitted infections, benign prostatic hyperplasia and lower urinary tract symptom-related outcomes: results from the Prostate, Lung, Colorectal and ovarian cancer Screening Trial.
Breyer BN; Huang WY; Rabkin CS; Alderete JF; Pakpahan R; Beason TS; Kenfield SA; Mabie J; Ragard L; Wolin KY; Grubb RL; Andriole GL; Sutcliffe S
BJU Int; 2016 Jan; 117(1):145-54. PubMed ID: 25601300
[TBL] [Abstract] [Full Text] [Related]
16. Clinical applicability of multi-tumor marker protein chips for diagnosing ovarian cancer.
Bian J; Li B; Kou XJ; Wang XN; Sun XX; Ming L
Asian Pac J Cancer Prev; 2014; 15(19):8409-11. PubMed ID: 25339038
[TBL] [Abstract] [Full Text] [Related]
17. To screen or nor to screen: the prostate cancer dilemma.
Stone NN; Crawford ED
Asian J Androl; 2015; 17(1):44-5. PubMed ID: 25337849
[TBL] [Abstract] [Full Text] [Related]
18. Predictions for the future of kallikrein-related peptidases in molecular diagnostics.
Scorilas A; Mavridis K
Expert Rev Mol Diagn; 2014 Jul; 14(6):713-22. PubMed ID: 24927162
[TBL] [Abstract] [Full Text] [Related]
19. [Metastases to the breast from non-mammary malignancies: a clinicopathologic study of 28 cases].
Zhou S; Yu B; Cheng Y; Xu X; Shui R; Bi R; Lu H; Tu X; Yang W
Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):231-5. PubMed ID: 24915812
[TBL] [Abstract] [Full Text] [Related]
20. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence.
Hayes JH; Barry MJ
JAMA; 2014 Mar; 311(11):1143-9. PubMed ID: 24643604
[TBL] [Abstract] [Full Text] [Related]
[Next]
